Menu
← Bio Talent Intelligence

BANSEOG BIO TALENT INTELLIGENCE

Pharma · COMPANY INTELLIGENCE

HANMI
PHARMACEUTICAL

We look for people who can reconfigure an asset and move it across development, manufacturing and partner boundaries—not only create new science.

TALENT PATTERN · 01Experience that can move a stalled or redirected asset again may become more valuable.
Company & HR — who should we look for? →Talent & Career — what should I build next? →
7 roles & capabilities observed4 business & hiring changes observed2 Talent Patterns published

TALENT PATTERNS

See which experience may become scarce first.

01ASSET RECONFIGURATION

TALENT CAPABILITY

Asset Reconfiguration

Development Path Rebuilder

The capability to reassess a stalled or redirected development asset, preserve what still matters and redesign the indication, development route or execution model so the asset can move again.

Repeating a successful project is different from deciding what to keep, what to discard and how to rebuild the route after the original path ends.

Core capability
  • Program Reassessment
  • Indication Reframing
  • Development-path Redesign
  • Recovery-to-Execution
Experience that strengthens it
  • Process Development
  • Medical / Clinical Context
  • Business Development
  • Manufacturing

Experience that can move a stalled or redirected asset again may become more valuable.

We look for people who can reassess remaining evidence after an earlier development path ends, redesign the indication or execution path and carry the asset into a real next stage.

Why nowHanmi is extending efpeglenatide through obesity and diabetes development while separately moving sonefpeglutide and HM17321 into global execution paths with Lilly and Genentech in 2026.

Company & HR

Who has rebuilt a development path after the original route stopped or changed?

Who should we look at first?Process / Clinical Development or BD depth plus ownership of program reassessment, indication change or development recovery
Where should we look?

Look across large-pharma R&D, lifecycle development, clinical strategy, CMC/process and licensing for people who have handled stopped, redirected or restarted programs.

What should we do next?

Test what assumption failed, what evidence was preserved, what was discarded and how the candidate moved the asset to a new milestone.

Hiring playbook

Search rule

Prioritize evidence of rebuilding a program after a stop, return or strategic change—not just the count of successful projects.

Evidence to test in interview

Ask what assumption broke, which evidence remained useful, what was discarded and why the new route was chosen.

Build internally

Give strong development and BD talent ownership of reassessment and redesign programs, not only linear programs.

Request analysis of this talent market →
View evidence6
Roles & capabilities
ManufacturingObserved again
Process DevelopmentObserved again
Business DevelopmentObserved again
Business changes
Genentech licenses HM17321 for worldwide development outside Korea2026-08-24Source ↗
Lilly licenses sonefpeglutide across development, manufacturing and commercialization2026-06-01Source ↗
Efpeglenatide enters a new Phase 3 diabetes development path2026-05-18Source ↗
02BOUNDARY-CROSSING EXECUTION

TALENT CAPABILITY

Boundary-Crossing Execution

Asset Handoff Builder

The capability to turn the output of one development stage into a state the next organization can actually use across process, manufacturing, quality, business and partner boundaries.

Producing a strong result inside one function is different from making that result executable by the next function.

Core capability
  • Development Handoff
  • Manufacturing Readiness
  • Partner-ready Package
  • Cross-functional Closure
Experience that strengthens it
  • Process Development
  • Manufacturing
  • Quality Assurance
  • Business Development

The scarce skill may be making your output usable by the next function—not only excelling inside your own stage.

We look for experience that carries a development result across process, manufacturing, quality, business or partner boundaries until the next organization can actually execute.

Why nowHanmi is connecting internal pipelines to late-stage development and Pyeongtaek operations while its 2026 global agreements also connect development, manufacturing and commercialization to external partner execution.

Company & HR

Who has actually moved an asset into its next operating state across function boundaries?

Who should we look at first?Depth in Process Development / Manufacturing / QA / BD plus ownership of readiness and handoff across at least two functions
Where should we look?

Look across pharma and biotech R&D, CMC/process, commercial manufacturing, QA, tech transfer and licensing for people who have closed real cross-functional handoffs.

What should we do next?

Ask who used the candidate’s output next, what conditions had to be met and which gaps the candidate personally closed before the next team could execute.

Hiring playbook

Search rule

Look beyond tenure for ownership of moving one asset across two or more functional boundaries.

Evidence to test in interview

Ask what the next team needed, which gaps blocked the handoff and what the candidate personally closed.

Build internally

Give strong specialists shared ownership of downstream readiness and the next function’s handoff conditions.

Request analysis of this talent market →
View evidence7
Roles & capabilities
Quality AssuranceObserved again
ManufacturingObserved again
Process DevelopmentObserved again
Business DevelopmentObserved again
Business changes
Pyeongtaek Bio Plant starts AI-assisted QA document operations2026-09-07Source ↗
Genentech licenses HM17321 for worldwide development outside Korea2026-08-24Source ↗
Lilly licenses sonefpeglutide across development, manufacturing and commercialization2026-06-01Source ↗

CURRENT EVIDENCE

Start with what is currently observed.

Current roles & capabilities

Quality AssuranceContinuing signalObserved again
ManufacturingContinuing signalObserved again
Process DevelopmentContinuing signalObserved again
Business DevelopmentContinuing signalObserved again
Quality ControlCurrently observed
EngineeringCurrently observed
Medical AffairsCurrently observed
Repeatedly observed pressure

Quality Assurance · Manufacturing · Process Development · Business Development

Business & hiring changes

2026-09-07 · Manufacturing changePyeongtaek Bio Plant starts AI-assisted QA document operations

Hanmi is applying Q-Agent first to QA work at the Pyeongtaek Bio Plant and plans to extend the operating model across quality and development functions.

Source ↗
2026-08-24 · PartnershipGenentech licenses HM17321 for worldwide development outside Korea

The agreement transfers broad ex-Korea development, manufacturing and commercialization rights while Hanmi retains Korea.

Source ↗
2026-06-01 · PartnershipLilly licenses sonefpeglutide across development, manufacturing and commercialization

The agreement moves a Hanmi-developed LAPSCOVERY asset into a global partner execution path spanning development through commercialization.

Source ↗
2026-05-18 · Pipeline changeEfpeglenatide enters a new Phase 3 diabetes development path

Hanmi is advancing efpeglenatide in a Phase 3 type 2 diabetes combination program, extending the asset beyond its earlier development path.

Source ↗
BANSEOG ANALYSISDevelopment assets are being reconfigured across internal execution and selective global amplification

CURRENT TALENT MARKET

Then see the talent market moving around it.

TALENT & CAREER

How far can my experience transfer?

No evidence-backed adjacent career path is currently linked.

COMPANY & HR

Who else is looking at the same talent?

No evidence-backed talent-competitor relationship is currently linked.